Drug Trial Radar · NCT01252719
Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
Last checked: Nov 19, 2026Latest source record: Aug 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
968
Actual
Start
Dec 2010
Primary completion
Oct 2012
Study completion Nov 30, 2012
Sponsor
- Lead sponsor
- Melinta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 3, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 3 trial was to evaluate the efficacy, safety, and tolerability of oritavancin in acute bacterial skin and skin structure infections (ABSSSIs), including those caused by methicillin-resistant staphylococcus aureus (MRSA), and to evaluate the potential economic benefit of oritavancin administered as a single 1200-milligram (mg) intravenous (IV) dose.
Conditions
- Wound Infection
- Abscess
- Systemic Inflammation
- Cellulitis
Interventions
Single-Dose IV Oritavancin DiphosphateDrug
Oritavancin was administered as a single IV dose.
IV VancomycinDrug
Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
PlaceboDrug
Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cessation Of Spread Or Reduction In Size Of Baseline Lesion, Absence Of Fever, And No Rescue Antibiotic Medication At Early Clinical Evaluation (ECE) (48 To 72 Hours)Time frame: 48-72 hours after the initiation of study therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sharp Chula Vista Medical Center
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.